Industry News
Pharmaceutical Industry News
BeOne Medicines has entered the…
BeOne Medicines has entered the BCL-2 arena, securing an FDA green light for Beqalzi that carves out a unique piece of territory ahead of a potential broader clash with market leader Venclexta.
How privacy-first data and…
How privacy-first data and data-driven TV are helping pharma brands cut waste and reach real patients.
Why siloed strategies fall short…
Why siloed strategies fall short and how integrated decision-making is reshaping pharmaceutical launches.
As President Trump lands in…
As President Trump lands in Beijing, one major industry is missing from his business delegation—pharma.
Meaningful involvement in MND…
Meaningful involvement in MND research ensures patient perspectives shape progress, making science relevant and compassionate.
The case for DTP is made. What…
The case for DTP is made. What separates programs that deliver from ones that stall? Gifthealth breaks down what it actually takes.
Under new CEO Kai Beckmann, Merck…
Under new CEO Kai Beckmann, Merck KGaA is emphasizing M&A to stock its early- to mid-stage pharma pipeline, the company said in reporting its first quarter results.
Takeda’s multiyear slim-down is…
Takeda's multiyear slim-down is expected to hit about 4,500 roles during the 2026 fiscal year, resulting in about 170 billion Japanese yen ($1.07 billion) in restructuring costs and some 100 billion yen ($633 million) in
The FDA has issued an untitled…
The FDA has issued an untitled letter to BeOne Medicines’ U.S. subsidiary over a TV commercial promoting its BTK blood cancer drug Brukinsa, saying the ad used “compelling and attention-grabbing visuals” that did not hold
Eli Lilly and Novo Nordisk are…
Eli Lilly and Novo Nordisk are building cases for their incretin drugs, both new and old, as attractive weight loss maintenance options and a potentially speedier option to shed pounds, respectively.
Haleon has completed a hat-trick…
Haleon has completed a hat-trick of recent soccer initiatives, inking a pain management partnership with the organization responsible for protecting the health and safety of players in Europe.
Patients arrive informed….
Patients arrive informed. Marketers must shift from visibility to usefulness to earn trust.
A new survey undertaken by the…
A new survey undertaken by the Harris Poll for Johnson & Johnson has shown how standard forms of surgery and treatment for certain bladder cancer patients are causing a major long-term emotional impact.
Shortly after locking down its…
Shortly after locking down its $4.8 billion deal for rare disease compatriot Amicus Therapeutics, BioMarin is consolidating the workforce tied to the acquired company’s headquarters in New Jersey
How an ‘Impossible’ Idea Led to a Pancreatic Cancer Breakthrough
The new strategy also holds promise for lung and colon tumors. Here’s how scientists discovered it.
Marty Makary, M.D., is resigning…
Marty Makary, M.D., is resigning as FDA commissioner Tuesday, ending a brief but tumultuous tenure marked by mounting criticism from all sides, according to reports.
Eli Lilly has paused an obesity…
Eli Lilly has paused an obesity awareness campaign in India in response to a regulatory notice regarding advertising rules for prescription medicines, Reuters reports.
Alkermes has chalked up a quick…
Alkermes has chalked up a quick clinical win from its $2.37 billion acquisition of Avadel, reporting Tuesday that a phase 3 study of the sodium oxybate drug Lumryz met all primary and key secondary endpoints
The deal includes up to $320…
The deal includes up to $320 million in future milestone payments plus tiered royalties on Veppanu sales, which will be split evenly between Arvinas and Pfizer.
After staving off significant…
After staving off significant sales declines for Eylea, Bayer is getting hit with full force by biosimilar competition for the eye disease treatment, which saw a 24% sales decline in the first quarter.